Hardman & Co Research

  • Land: United Kingdom

Nachricht vom 14.06.2018 | 10:50

Hardman & Co Research: Oxford BioMedica (OXB): Gene-therapy for Parkinson's: clinical progression

Hardman & Co Research

14-Jun-2018 / 09:50 GMT/BST


Hardman & Co Research: Gene-therapy for Parkinson's: clinical progression

OXB is a specialist advanced-therapy lentivirus vector biopharma company. It offers vector manufacturing and development services, and also has a proprietary drug pipeline. In addition to LentiVector(R) service contracts, OXB receives royalties on commercial therapies developed by its partners using the LentiVector platform. A partnership deal structure was established with Novartis for KymriahPPPTM in 2017,PP and was followed by a collaboration and licence agreement with Bioverativ Inc in February 2018. The latest deal, on 6 June 2018, is the first involving OXB's proprietary platform: it will advance the Parkinson's disease gene-therapy to the clinic. Please click here for the full report:

http://www.hardmanandco.com/docs/default-source/company-docs/oxford-biomedica-documents/14.06.18-gene-therapy-for-parkinsons-clinical-progression.pdf

 

To contact us:

Hardman & Co
35 New Broad Street
London
EC2M 1NH
www.hardmanandco.com
Follow us on Twitter @HardmanandCo
Contacts:

Dorothea Hill

+44 20 7194 7626


dmh@hardmanandco.com
 

Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.

About Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.



Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

show this

Interview im Fokus

„Vorteile überwiegen deutlich“

Seit dem 1. Juni notiert die Mutares-Beteiligung STS Group AG im Prime Standard. „Die Platzierung der STS Group ist eine der erfolgreichsten Transaktionen in der Geschichte der Mutares AG. Neben dem Exiterlös von über 31 Mio. Euro partizipieren wir als Mehrheitsaktionär auch weiterhin maßgeblich an der Wertentwicklung der STS Group“, so Mutares-CEO Robin Laik gegenüber Financial.de. „Die Platzierung wird einen stark positiven Einfluss auf das Ergebnis des Geschäftsjahres 2018 haben.“

GBC im Fokus

Über 50% Kurschance bei Homes & Holiday AG, Börsengang läuft!

Der Ferienimmobilienspezialist geht zur Wachstumsbeschleunigung an die Börse. Die Zeichnungsfrist für die Homes & Holiday-Aktie (DE000A2GS5M9) läuft noch bis zum 21. Juni, Zeichnungen sind möglich per Kauforder am Börsenplatz München zu einem Preis von 2,50 €. Die Positionierung in Europas attraktivsten Ferienimmobilienregionen ist hervorragend. In Mallorca ist die Tochtergesellschaft Porta Mallorquina unter den TOP-3-Maklerhäusern, der Fokus des weiteren Wachstum liegt auf Standorten in Spanien und Deutschland. Dort befinden sich die Preise im starken Aufwärtstrend. Unser Research sieht den fairen Wert nach IPO bei 4,83 € je Aktie und damit eine hohe Kurschance.

News im Fokus

Vonovia mit Victoria Park Angebot erfolgreich

18. Juni 2018, 21:46

Aktuelle Research-Studie

Original-Research: Golden Dawn Minerals Inc. (von First Berlin Equity Research GmbH): Kaufen Golden Dawn Minerals Inc.

19. Juni 2018